IN BRIEF: Shield receives approval from South Korea for Accrufer
7th Nov 2025 17:03
(Alliance News) - Shield Therapeutics PLC - Newcastle, England-based commercial-stage pharmaceutical company - Announces that the Korean Ministry of Food and Drug Safety has granted regulatory approval for Accrufer in South Korea for the treatment of iron deficiency in adult subjects. The approval follows submission of a new drug application by Korea Pharma in 2024 after the successful completion of a pharmacokinetic study. Shield is eligible to receive payments upon the first sale, as well as performance-based sales milestones and royalties on net sales. Read More